Peptilogics, a clinical-stage biotech developing surgical therapeutics to prevent medical device infections, closed a $78M Series B2 financing. The round was led by Presight Capital, Thiel Bio and Founders Fund, with participation from AMR Action Fund, Narya Capital and Beyond Ventures.
Comments
Want to join the conversation?
Loading comments...